Phase 1 HIV and AIDS Trial, Recruiting NCT05334004 Sponsor: University of Wisconsin, Madison Condition: HIV and AIDS
Back to Hiv Aids

Phase 1 HIV and AIDS Trial, Recruiting

NCT05334004
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to give their agreement to take part in the study (informed consent)
  • People who are 18 years of age or older
  • People who have been diagnosed with high-grade anal dysplasia (a type of abnormal cell growth in the anal area), confirmed by a tissue biopsy
  • People who are willing to follow all study procedures throughout the trial

Who may not be able to join:

  • People who have been diagnosed with low-grade anal dysplasia (a less severe form of abnormal cell changes in the anal area), as identified by a specialised examination procedure
  • People whose immune cell count (specifically CD4 cells) is below 200 cells per cubic millimetre of blood at the time the trial site considers them for entry
  • People who are unable to give their agreement to take part in the study
  • People who are pregnant or currently breastfeeding
  • People who are currently receiving chemotherapy or radiation treatment for another cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Evie Carchman, MD, FACS, University of Wisconsin, Madison

Phone: 800-622-8922

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
19 December 2023
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum Tolerated Dose (MTD) as determined by the number of participants at each dose level in the escalation cohorts who experienced a dose-limiting toxicity (DLT); Rate of Grade 3 or above Toxicities in any Organ System in the Escalation Cohorts

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov